

NexoBrid®

Disruptive Therapy for Burn Care FDA and EMA approved

- Approved in 40+ countries; 16,000+ patients treated to date
- Poised to replace standard of care for eschar removal in severe burns
- Minimizes need for surgery and significantly reduces blood loss
- Topical application at bedside
- Preserves viable tissue and improves patient outcomes (scar quality and function)
- c-GMP sterile manufacturing facility to support global demand



EscharEx®

Bioactive Enzymatic Debridement Drug Candidate for Chronic Wounds

- Rapid, effective debridement and facilitation of wound closure for Venous Leg Ulcers (VLU) and Diabetic Foot Ulcers (DFU)
- Easy to use topical application for all patient settings
- Debrides chronic ulcers within 4-8 applications
- Promotes granulation tissue and reduces bacteria & biofilm
- Demonstrated superiority over SANTYL®
- Targets a \$2.5B+ market
- De-risked program: based on 3 successful Phase II trials
 - Ongoing Phase III trial for VLU
 - DFU trial planned for H2 2026
- Research collaborations with Mölnlycke, Solventum, Coloplast, Convatec, MIMEDX and Essity



Global Collaborations



Validated Enzymatic Technology Platform

Solid Balance Sheet

\$60M cash (as of Sept 30, 2025)

\$20M revenues in 2024

\$115M+ BARDA funding (to date)

\$20M+ DoD funding (to date)